Antisense Therapeutics:
Announcement of the complete sequencing of the human genome in April 2003 demonstrated the presence of thousands of targets for antisense oligonucleotides and opened the way to hundreds of preclinical animal studies and some 20 ongoing clinical trials. In this second edition of Antisense Therapeutic...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Totowa, NJ
Humana Press
2005
|
| Ausgabe: | Second Edition |
| Schriftenreihe: | Methods in Molecular Medicine™
106 |
| Schlagworte: | |
| Online-Zugang: | UBR01 TUM01 Volltext |
| Zusammenfassung: | Announcement of the complete sequencing of the human genome in April 2003 demonstrated the presence of thousands of targets for antisense oligonucleotides and opened the way to hundreds of preclinical animal studies and some 20 ongoing clinical trials. In this second edition of Antisense Therapeutics, a team of leading researchers and clinical scientists demonstrate the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery. Highlights include RNA-based therapies for many diseases, up-to-date methods and applications, and insight into the enormous potential to provide a new generation of drugs. Highly practical and disease oriented, Antisense Therapeutics, Second Edition offers not only a primer for a new generation of drug discovery researchers, but also an illuminating exploration of the potential in exploiting RNA inhibition for novel human therapeutics |
| Beschreibung: | 1 Online-Ressource (344 p. 56 illus) |
| ISBN: | 9781592598540 |
| DOI: | 10.1385/1592598544 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV044952415 | ||
| 003 | DE-604 | ||
| 005 | 20180829 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 180517s2005 |||| o||u| ||||||eng d | ||
| 020 | |a 9781592598540 |9 978-1-59259-854-0 | ||
| 024 | 7 | |a 10.1385/1592598544 |2 doi | |
| 035 | |a (ZDB-2-PRO)978-1-59259-854-0 | ||
| 035 | |a (OCoLC)712421412 | ||
| 035 | |a (DE-599)BVBBV044952415 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-91 | ||
| 050 | 0 | |a RM666.A564 | |
| 082 | 0 | |a 571.6 |2 23 | |
| 082 | 0 | |a 615/.31 |2 22 | |
| 084 | |a WD 5350 |0 (DE-625)148200: |2 rvk | ||
| 245 | 1 | 0 | |a Antisense Therapeutics |c edited by M. Ian Phillips |
| 250 | |a Second Edition | ||
| 264 | 1 | |a Totowa, NJ |b Humana Press |c 2005 | |
| 300 | |a 1 Online-Ressource (344 p. 56 illus) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Methods in Molecular Medicine™ |v 106 | |
| 520 | |a Announcement of the complete sequencing of the human genome in April 2003 demonstrated the presence of thousands of targets for antisense oligonucleotides and opened the way to hundreds of preclinical animal studies and some 20 ongoing clinical trials. In this second edition of Antisense Therapeutics, a team of leading researchers and clinical scientists demonstrate the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery. Highlights include RNA-based therapies for many diseases, up-to-date methods and applications, and insight into the enormous potential to provide a new generation of drugs. Highly practical and disease oriented, Antisense Therapeutics, Second Edition offers not only a primer for a new generation of drug discovery researchers, but also an illuminating exploration of the potential in exploiting RNA inhibition for novel human therapeutics | ||
| 650 | 4 | |a Life Sciences | |
| 650 | 4 | |a Cell Biology | |
| 650 | 4 | |a Life sciences | |
| 650 | 4 | |a Cell biology | |
| 650 | 0 | 7 | |a Antisense-Nucleinsäuren |0 (DE-588)4282992-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Molekulare Medizin |0 (DE-588)4543844-4 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Antisense-Nucleinsäuren |0 (DE-588)4282992-6 |D s |
| 689 | 0 | 1 | |a Molekulare Medizin |0 (DE-588)4543844-4 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 700 | 1 | |a Phillips, M. Ian |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781588292056 |
| 856 | 4 | 0 | |u https://doi.org/10.1385/1592598544 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-PRO | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-030345170 | ||
| 966 | e | |u https://doi.org/10.1385/1592598544 |l UBR01 |p ZDB-2-PRO |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1385/1592598544 |l TUM01 |p ZDB-2-PRO |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804178542260387840 |
|---|---|
| any_adam_object | |
| author2 | Phillips, M. Ian |
| author2_role | edt |
| author2_variant | m i p mi mip |
| author_facet | Phillips, M. Ian |
| building | Verbundindex |
| bvnumber | BV044952415 |
| callnumber-first | R - Medicine |
| callnumber-label | RM666 |
| callnumber-raw | RM666.A564 |
| callnumber-search | RM666.A564 |
| callnumber-sort | RM 3666 A564 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| classification_rvk | WD 5350 |
| collection | ZDB-2-PRO |
| ctrlnum | (ZDB-2-PRO)978-1-59259-854-0 (OCoLC)712421412 (DE-599)BVBBV044952415 |
| dewey-full | 571.6 615/.31 |
| dewey-hundreds | 500 - Natural sciences and mathematics 600 - Technology (Applied sciences) |
| dewey-ones | 571 - Physiology & related subjects 615 - Pharmacology and therapeutics |
| dewey-raw | 571.6 615/.31 |
| dewey-search | 571.6 615/.31 |
| dewey-sort | 3571.6 |
| dewey-tens | 570 - Biology 610 - Medicine and health |
| discipline | Biologie Medizin |
| doi_str_mv | 10.1385/1592598544 |
| edition | Second Edition |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02927nmm a2200529zcb4500</leader><controlfield tag="001">BV044952415</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20180829 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">180517s2005 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781592598540</subfield><subfield code="9">978-1-59259-854-0</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1385/1592598544</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-PRO)978-1-59259-854-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)712421412</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044952415</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-91</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM666.A564</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">571.6</subfield><subfield code="2">23</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.31</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WD 5350</subfield><subfield code="0">(DE-625)148200:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antisense Therapeutics</subfield><subfield code="c">edited by M. Ian Phillips</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">Second Edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Totowa, NJ</subfield><subfield code="b">Humana Press</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (344 p. 56 illus)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Methods in Molecular Medicine™</subfield><subfield code="v">106</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Announcement of the complete sequencing of the human genome in April 2003 demonstrated the presence of thousands of targets for antisense oligonucleotides and opened the way to hundreds of preclinical animal studies and some 20 ongoing clinical trials. In this second edition of Antisense Therapeutics, a team of leading researchers and clinical scientists demonstrate the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery. Highlights include RNA-based therapies for many diseases, up-to-date methods and applications, and insight into the enormous potential to provide a new generation of drugs. Highly practical and disease oriented, Antisense Therapeutics, Second Edition offers not only a primer for a new generation of drug discovery researchers, but also an illuminating exploration of the potential in exploiting RNA inhibition for novel human therapeutics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Life Sciences</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cell Biology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Life sciences</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cell biology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antisense-Nucleinsäuren</subfield><subfield code="0">(DE-588)4282992-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Molekulare Medizin</subfield><subfield code="0">(DE-588)4543844-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Antisense-Nucleinsäuren</subfield><subfield code="0">(DE-588)4282992-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Molekulare Medizin</subfield><subfield code="0">(DE-588)4543844-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Phillips, M. Ian</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781588292056</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1385/1592598544</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-PRO</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030345170</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1385/1592598544</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-PRO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1385/1592598544</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-2-PRO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV044952415 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:05:37Z |
| institution | BVB |
| isbn | 9781592598540 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030345170 |
| oclc_num | 712421412 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
| owner_facet | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
| physical | 1 Online-Ressource (344 p. 56 illus) |
| psigel | ZDB-2-PRO |
| publishDate | 2005 |
| publishDateSearch | 2005 |
| publishDateSort | 2005 |
| publisher | Humana Press |
| record_format | marc |
| series2 | Methods in Molecular Medicine™ |
| spelling | Antisense Therapeutics edited by M. Ian Phillips Second Edition Totowa, NJ Humana Press 2005 1 Online-Ressource (344 p. 56 illus) txt rdacontent c rdamedia cr rdacarrier Methods in Molecular Medicine™ 106 Announcement of the complete sequencing of the human genome in April 2003 demonstrated the presence of thousands of targets for antisense oligonucleotides and opened the way to hundreds of preclinical animal studies and some 20 ongoing clinical trials. In this second edition of Antisense Therapeutics, a team of leading researchers and clinical scientists demonstrate the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery. Highlights include RNA-based therapies for many diseases, up-to-date methods and applications, and insight into the enormous potential to provide a new generation of drugs. Highly practical and disease oriented, Antisense Therapeutics, Second Edition offers not only a primer for a new generation of drug discovery researchers, but also an illuminating exploration of the potential in exploiting RNA inhibition for novel human therapeutics Life Sciences Cell Biology Life sciences Cell biology Antisense-Nucleinsäuren (DE-588)4282992-6 gnd rswk-swf Molekulare Medizin (DE-588)4543844-4 gnd rswk-swf Antisense-Nucleinsäuren (DE-588)4282992-6 s Molekulare Medizin (DE-588)4543844-4 s b DE-604 Phillips, M. Ian edt Erscheint auch als Druck-Ausgabe 9781588292056 https://doi.org/10.1385/1592598544 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Antisense Therapeutics Life Sciences Cell Biology Life sciences Cell biology Antisense-Nucleinsäuren (DE-588)4282992-6 gnd Molekulare Medizin (DE-588)4543844-4 gnd |
| subject_GND | (DE-588)4282992-6 (DE-588)4543844-4 |
| title | Antisense Therapeutics |
| title_auth | Antisense Therapeutics |
| title_exact_search | Antisense Therapeutics |
| title_full | Antisense Therapeutics edited by M. Ian Phillips |
| title_fullStr | Antisense Therapeutics edited by M. Ian Phillips |
| title_full_unstemmed | Antisense Therapeutics edited by M. Ian Phillips |
| title_short | Antisense Therapeutics |
| title_sort | antisense therapeutics |
| topic | Life Sciences Cell Biology Life sciences Cell biology Antisense-Nucleinsäuren (DE-588)4282992-6 gnd Molekulare Medizin (DE-588)4543844-4 gnd |
| topic_facet | Life Sciences Cell Biology Life sciences Cell biology Antisense-Nucleinsäuren Molekulare Medizin |
| url | https://doi.org/10.1385/1592598544 |
| work_keys_str_mv | AT phillipsmian antisensetherapeutics |